Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing

1 hour ago 2

Jake Lerch, The Motley Fool

Thu, March 5, 2026 astatine 9:14 AM CST 4 min read

On February 17, 2026, Boxer Capital Management, LLC disclosed a caller presumption successful Terns Pharmaceuticals (NASDAQ:TERN), acquiring 375,000 shares successful a transaction estimated astatine $15.15 cardinal based connected quarterly mean pricing.

Boxer Capital Management, LLC disclosed a caller presumption successful Terns Pharmaceuticals, according to its SEC filing dated February 17, 2026. The money reported acquiring 375,000 shares during the 4th quarter, with the estimated transaction worth astatine $15.15 cardinal based connected the mean terms implicit the period. The quarter-end worth of the Terns Pharmaceuticals involvement roseate by $15.15 million, reflecting the combined interaction of stock purchases and terms changes.

This caller presumption present represents 3.32% of Boxer Capital’s $456.88 cardinal successful 13F reportable assets nether management.

Top holdings aft the filing:

NASDAQ: TNGX: $96.36 cardinal (21.1% of AUM)
NASDAQ: RVMD: $31.86 cardinal (7.0% of AUM)
NASDAQ: KOD: $31.76 cardinal (7.0% of AUM)
NASDAQ: KYMR: $25.61 cardinal (5.6% of AUM)
NASDAQ: CELC: $22.44 cardinal (4.9% of AUM)

As of February 17, 2026, shares were priced astatine $39.58, up 858.4% implicit the past year, outperforming the S&P 500 by 862.96 percent points.

Metric

Value

Price (as of marketplace adjacent 2/17/26)	$39.58
Market capitalization	$3.57 billion
Employees	59
One-year terms change	858.35%

Develops small-molecule therapies targeting non-alcoholic steatohepatitis (NASH) and obesity, with pb candidates including TERN-101, TERN-201, TERN-501, and TERN-601 successful assorted objective proceedings phases.
Operates arsenic a clinical-stage biopharmaceutical company, generating worth done the improvement and imaginable aboriginal commercialization oregon out-licensing of proprietary cause candidates.
Serves pharmaceutical markets focused connected metabolic and liver diseases, with superior customers expected to see healthcare providers and patients affected by NASH and obesity.

Terns Pharmaceuticals is simply a clinical-stage biotechnology institution specializing successful the improvement of caller therapies for liver and metabolic diseases. With a focused pipeline targeting NASH and obesity, the institution leverages proprietary small-molecule candidates to code important unmet aesculapian needs. Its strategical accent connected differentiated mechanisms and liver-targeted transportation positions it competitively wrong the biopharmaceutical sector.

Boxer Capital, a California-based concern firm, precocious disclosed the acquisition of 375,000 shares of Terns Pharmaceuticals. Here’s what investors should know.

Read Entire Article